Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.57 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4317092 | 0.84 | CYP17A1 (0.60) | LTA4HSAE1UBA2 | |
| SCHEMBL1425001 | 0.81 | LTA4H (0.81) | LTA4HSAE1UBA2IDO1ALDH1A1 | |
| SCHEMBL25986524 | 0.81 | LTA4H (0.81) | LTA4HSAE1UBA2IDO1ALDH1A1 | |
| SCHEMBL27884 | 0.81 | LTA4H (0.81) | LTA4HSAE1UBA2IDO1ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL20919857 | 0.79 | LTA4H (0.77) | LTA4HSAE1UBA2IDO1ALDH1A1 | |
| SCHEMBL9357255 | 0.78 | TAAR1 (0.56) | LTA4HALDH1A1TAAR1 | |
| SCHEMBL20751464 | 0.78 | IDH1 (0.46) | LTA4HIDO1ALDH1A1TAAR1 | |
| SCHEMBL27968336 | 0.78 | DRD2 (0.44) | LTA4HALDH1A1TAAR1 | |
| SCHEMBL5684056 | 0.76 | LTA4H (0.48) | LTA4HALDH1A1TAAR1 | |
| SCHEMBL27883071 | 0.76 | MCHR1 (0.38) | LTA4HTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022263800-A1 | PROCESS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2022-12-22 | — | — | WO | disclosed |
| CN-103467481-B | Dihydropyridine compounds, a combination thereof thing, preparation method and purposes | 上海汇伦生命科技有限公司 | 2016-08-31 | — | — | CN | disclosed |
| EP-1609785-B1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC (JP) | 2016-02-03 | — | — | EP | disclosed |
| EP-1609785-B1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | ASTELLAS PHARMA INC (JP) | 2016-02-03 | — | — | EP | disclosed |
| CN-102627657-B | Synthetic method of 3-(4-methoxy-benzyl)-1H-pyrimidine-2,4-dione derivative | SUZHOU SHIYA BIOPHARMACEUTICALS INC | 2015-01-07 | — | — | CN | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977466-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-1980560-B1 | C-glycoside derivatives for the treatment of diabetes | ASTELLAS PHARMA INC (JP) | 2011-05-25 | — | — | EP | disclosed |
| EP-1980560-A2 | C-glycoside derivatives for the treatment of diabetes | Astellas Pharma Inc. (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| US-7202350-B2 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2007-04-10 | — | — | US | disclosed |
| CN-1802366-A | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC (JP) | 2006-07-12 | — | — | CN | disclosed |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | ASTELLAS PHARMA INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| EP-1609785-A1 | C-GLYCOSIDE DERIVATIVES AND SALTS THEREOF | Astellas Pharma Inc. (JP) | 2005-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161787-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | LTA4H 4448/4885SAE1 1589/4885UBA2 3104/4885 |
| US-20060122126-A1 | C-glycoside derivatives and salts thereof | SLC5A1, SLC5A2, SLC2A1 | LTA4H 4448/4885SAE1 1589/4885UBA2 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.